[1]
|
Mcdonagh, T.A., Metra, M., Adamo, M., et al. (2021) 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. European Heart Journal, 42, 3599-3726. https://doi.org/10.1093/eurheartj/ehab368
|
[2]
|
Heidenreich, P.A., Bozkurt, B., Aguilar, D., et al. (2022) 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, E895-E1032. https://doi.org/10.1161/CIR.0000000000001063
|
[3]
|
Kraigher-Krainer, E., Shah, A.M., Gupta, D.K., et al. (2014) Impaired Systolic Function by Strain Imaging in Heart Failure with Preserved Ejection Fraction. Journal of the American College of Cardiology, 63, 447-456. https://doi.org/10.1016/j.jacc.2013.09.052
|
[4]
|
Ge, J. (2020) Coding Proposal on Phenotyping Heart Failure with Preserved Ejection Fraction: A Practical Tool for Facilitating Etiology-Oriented Therapy. Cardiology Journal, 27, 97-98. https://doi.org/10.5603/CJ.2020.0023
|
[5]
|
Kitzman, D.W., Gardin, J.M., Gottdiener, J.S., et al. (2001) Importance of Heart Failure with Preserved Systolic Function in Patients > or = 65 Years of Age. CHS Research Group. Cardiovascular Health Study. American Journal of Cardiology, 87, 413-419. https://doi.org/10.1016/S0002-9149(00)01393-X
|
[6]
|
Heidenreich, P.A., Albert, N.M., Allen, L.A., et al. (2013) Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association. Circulation: Heart Failure, 6, 606-619. https://doi.org/10.1161/HHF.0b013e318291329a
|
[7]
|
Owan, T.E., Hodge, D.O., Herges, R.M., et al. (2006) Trends in Prevalence and Outcome of Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine, 355, 251-259. https://doi.org/10.1056/NEJMoa052256
|
[8]
|
Shah, S.J., Kitzman, D.W., Borlaug, B.A., et al. (2016) Phenotype-Specific Treatment of Heart Failure with Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation, 134, 73-90. https://doi.org/10.1161/CIRCULATIONAHA.116.021884
|
[9]
|
Vaduganathan, M., Claggett, B.L., Desai, A.S., et al. (2020) Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF. Journal of the American College of Cardiology, 75, 245-254. https://doi.org/10.1016/j.jacc.2019.11.003
|
[10]
|
Mohammed, S.F., Borlaug, B.A., Roger, V.L., et al. (2012) Comorbidity and Ventricular and Vascular Structure and Function in Heart Failure with Preserved Ejection Fraction: A Community-Based Study. Circulation: Heart Failure, 5, 710-719. https://doi.org/10.1161/CIRCHEARTFAILURE.112.968594
|
[11]
|
Zakeri, R. and Cowie, M.R. (2018) Heart Failure with Preserved Ejection Fraction: Controversies, Challenges and Future Directions. Heart, 104, 377-384. https://doi.org/10.1136/heartjnl-2016-310790
|
[12]
|
Pfeffer, M.A., Shah, A.M. and Borlaug, B.A. (2019) Heart Failure with Preserved Ejection Fraction in Perspective. Circulation Research, 124, 1598-1617. https://doi.org/10.1161/CIRCRESAHA.119.313572
|
[13]
|
Gevaert, A.B., Kataria, R., Zannad, F., et al. (2022) Heart Failure with Preserved Ejection Fraction: Recent Concepts in Diagnosis, Mechanisms and Management. Heart, 108, 1342-1350. https://doi.org/10.1136/heartjnl-2021-319605
|
[14]
|
Camici, P.G., Tschöpe, C., Di Carli, M.F., et al. (2020) Coronary Microvascular Dysfunction in Hypertrophy and Heart Failure. Cardiovascular Research, 116, 806-816. https://doi.org/10.1093/cvr/cvaa023
|
[15]
|
射血分数保留的心力衰竭诊断与治疗中国专家共识制定工作组. 射血分数保留的心力衰竭诊断与治疗中国专家共识2023[J]. 中国循环杂志, 2023, 38(4): 375-393.
|
[16]
|
Haykowsky, M.J., Kouba, E.J., Brubaker, P.H., et al. (2014) Skeletal Muscle Composition and Its Relation to Exercise Intolerance in Older Patients with Heart Failure and Preserved Ejection Fraction. American Journal of Cardiology, 113, 1211-1216. https://doi.org/10.1016/j.amjcard.2013.12.031
|
[17]
|
Cowley, A.W., Abe, M., Mori, T., et al. (2015) Reactive Oxygen Species as Important Determinants of Medullary Flow, Sodium Excretion, and Hypertension. American Journal of Physiology-Renal Physiology, 308, F179-F197. https://doi.org/10.1152/ajprenal.00455.2014
|
[18]
|
Packer, M. (2018) Epicardial Adipose Tissue May Mediate Deleterious Effects of Obesity and Inflammation on the Myocardium. Journal of the American College of Cardiology, 71, 2360-2372. https://doi.org/10.1016/j.jacc.2018.03.509
|
[19]
|
Zile, M.R., Baicu, C.F., Ikonomidis, J.S., et al. (2015) Myocardial Stiffness in Patients with Heart Failure and a Preserved Ejection Fraction: Contributions of Collagen and Titin. Circulation, 131, 1247-1259. https://doi.org/10.1161/CIRCULATIONAHA.114.013215
|
[20]
|
Paulus, W.J. (2020) Unfolding Discoveries in Heart Failure. The New England Journal of Medicine, 382, 679-682. https://doi.org/10.1056/NEJMcibr1913825
|
[21]
|
Van Woerden, G., Gorter, T.M., Westenbrink, B.D., et al. (2018) Epicardial Fat in Heart Failure Patients with Mid-Range and Preserved Ejection Fraction. European Journal of Heart Failure, 20, 1559-1566. https://doi.org/10.1002/ejhf.1283
|
[22]
|
Shah, S.J., Lam, C.S., Svedlund, S., et al. (2018) Prevalence and Correlates of Coronary Microvascular Dysfunction in Heart Failure with Preserved Ejection Fraction: PROMIS-HFpEF. European Heart Journal, 39, 3439-3450. https://doi.org/10.1093/eurheartj/ehy531
|
[23]
|
Venkateshvaran, A., Faxen, U.L., Hage, C., et al. (2022) Association of Epicardial Adipose Tissue with Proteomics, Coronary Flow Reserve, Cardiac Structure and Function, and Quality of Life in Heart Failure with Preserved Ejection Fraction: Insights from the PROMIS-HFpEF Study. European Journal of Heart Failure, 24, 2251-2260. https://doi.org/10.1002/ejhf.2709
|
[24]
|
Paulus, W.J. and Tschöpe, C. (2013) A Novel Paradigm for Heart Failure with Preserved Ejection Fraction: Comorbidities Drive Myocardial Dysfunction and Remodeling through Coronary Microvascular Endothelial Inflammation. Journal of the American College of Cardiology, 62, 263-271. https://doi.org/10.1016/j.jacc.2013.02.092
|
[25]
|
Richards, A.M. (2018) N-Terminal B-Type Natriuretic Peptide in Heart Failure. Heart Failure Clinics, 14, 27-39. https://doi.org/10.1016/j.hfc.2017.08.004
|
[26]
|
Michaud, M., Maurin, V., Simon, M., et al. (2019) Patients with High Left Ventricular Filling Pressure May Be Missed Applying 2016 Echo Guidelines: A Pilot Study. The International Journal of Cardiovascular Imaging, 35, 2157-2166. https://doi.org/10.1007/s10554-019-01667-w
|
[27]
|
Chow, S.L., Maisel, A.S., Anand, I., et al. (2017) Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement from the American Heart Association. Circulation, 135, E1054-E1091. https://doi.org/10.1161/CIR.0000000000000490
|
[28]
|
Obokata, M., Reddy, Y.N.V., Pislaru, S.V., et al. (2017) Evidence Supporting the Existence of a Distinct Obese Phenotype of Heart Failure with Preserved Ejection Fraction. Circulation, 136, 6-19. https://doi.org/10.1161/CIRCULATIONAHA.116.026807
|
[29]
|
Anjan, V, Y., Loftus, T, M., Burke, M, A., et al. (2012) Prevalence, Clinical Phenotype, and Outcomes Associated with Normal B-Type Natriuretic Peptide Levels in Heart Failure with Preserved Ejection Fraction. American Journal of Cardiology, 110, 870-876. https://doi.org/10.1016/j.amjcard.2012.05.014
|
[30]
|
Obokata, M., Kane, G.C., Reddy, Y.N., et al. (2017) Role of Diastolic Stress Testing in the Evaluation for Heart Failure with Preserved Ejection Fraction: A Simultaneous Invasive-Echocardiographic Study. Circulation, 135, 825-838. https://doi.org/10.1161/CIRCULATIONAHA.116.024822
|
[31]
|
Obokata, M., Olson, T.P., Reddy, Y.N.V., et al. (2018) Haemodynamics, Dyspnoea, and Pulmonary Reserve in Heart Failure with Preserved Ejection Fraction. European Heart Journal, 39, 2810-2821. https://doi.org/10.1093/eurheartj/ehy268
|
[32]
|
Sugumar, H., Nanayakkara, S., Vizi, D., et al. (2021) A Prospective Study Using Invasive Haemodynamic Measurements Following Catheter Ablation for AF and Early HFpEF: STALL AF-HFpEF. European Journal of Heart Failure, 23, 785-796. https://doi.org/10.1002/ejhf.2122
|
[33]
|
Reddy, Y.N.V., Carter, R.E., Obokata, M., et al. (2018) A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure with Preserved Ejection Fraction. Circulation, 138, 861-870. https://doi.org/10.1161/CIRCULATIONAHA.118.034646
|
[34]
|
Pieske, B., Tschöpe, C., De Boer, R.A., et al. (2019) How to Diagnose Heart Failure with Preserved Ejection Fraction: The HFA-PEFF Diagnostic Algorithm: A Consensus Recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 40, 3297-3317. https://doi.org/10.1093/eurheartj/ehz641
|
[35]
|
Churchill, T.W., Li, S.X., Curreri, L., et al. (2021) Evaluation of 2 Existing Diagnostic Scores for Heart Failure with Preserved Ejection Fraction against a Comprehensively Phenotyped Cohort. Circulation, 143, 289-291. https://doi.org/10.1161/CIRCULATIONAHA.120.050757
|
[36]
|
Reddy, Y.N.V., Kaye, D.M., Handoko, M.L., et al. (2022) Diagnosis of Heart Failure with Preserved Ejection Fraction among Patients with Unexplained Dyspnea. JAMA Cardiology, 7, 891-899. https://doi.org/10.1001/jamacardio.2022.1916
|
[37]
|
Smiseth, O.A., Donal, E., Boe, E., et al. (2023) Phenotyping Heart Failure by Echocardiography: Imaging of Ventricular Function and Haemodynamics at Rest and Exercise. European Heart Journal-Cardiovascular Imaging, 24, 1329-1342. https://doi.org/10.1093/ehjci/jead196
|
[38]
|
Ma, C.S., Liao, Y.P., Fan, J.L., et al. (2022) The Novel Left Atrial Strain Parameters in Diagnosing of Heart Failure with Preserved Ejection Fraction. Echocardiography, 39, 416-425. https://doi.org/10.1111/echo.15304
|
[39]
|
Nagueh, S.F. (2023) Noninvasive Measurement of Left Atrial Stiffness in Patients with Heart Failure and Preserved Ejection Fraction. American College of Cardiology Foundation, Washington DC, 446-449. https://doi.org/10.1016/j.jcmg.2022.12.003
|
[40]
|
Kim, D., Seo, J.H., Choi, K.H., et al. (2023) Prognostic Implications of Left Atrial Stiffness Index in Heart Failure Patients with Preserved Ejection Fraction. Cardiovascular Imaging, 16, 435-445. https://doi.org/10.1016/j.jcmg.2022.11.002
|
[41]
|
Liu, Y., Guo, X. and Zheng, Y. (2019) An Automatic Approach Using ELM Classifier for HFpEF Identification Based on Heart Sound Characteristics. Journal of Medical Systems, 43, Article No. 285. https://doi.org/10.1007/s10916-019-1415-1
|
[42]
|
Zheng, Y., Guo, X., Qin, J., et al. (2015) Computer-Assisted Diagnosis for Chronic Heart Failure by the Analysis of Their Cardiac Reserve and Heart Sound Characteristics. Computer Methods and Programs in Biomedicine, 122, 372-383. https://doi.org/10.1016/j.cmpb.2015.09.001
|
[43]
|
Cheng, L., Liao, K., Wang, Y., et al. (2021) Study of the Correlation between the Ratio of Diastolic to Systolic Durations and Echocardiography Measurements and Its Application to the Classification of Heart Failure Phenotypes. International Journal of General Medicine, 14, 5493-5503. https://doi.org/10.2147/IJGM.S324319
|
[44]
|
Luo, H., Weerts, J., Bekkers, A., et al. (2023) Association between Phonocardiography and Echocardiography in Heart Failure Patients with Preserved Ejection Fraction. European Heart Journal—Digital Health, 4, 4-11. https://doi.org/10.1093/ehjdh/ztac073
|
[45]
|
Sujadevi, V.G., Soman, K.P., Vinayakumar, R., et al. (2017) Deep Models for Phonocardiography (PCG) Classification. 2017 International Conference on Intelligent Communication and Computational Techniques: ICCT 2017, Jaipur, 22-23 December 2017, 211-216. https://doi.org/10.1109/INTELCCT.2017.8324047
|
[46]
|
Cheng, R.K., Cox, M., Neely, M.L., et al. (2014) Outcomes in Patients with Heart Failure with Preserved, Borderline, and Reduced Ejection Fraction in the Medicare Population. American Heart Journal, 168, 721-730. https://doi.org/10.1016/j.ahj.2014.07.008
|
[47]
|
Massie, B.M., Carson, P.E., Mcmurray, J.J., et al. (2008) Irbesartan in Patients with Heart Failure and Preserved Ejection Fraction. New England Journal of Medicine, 359, 2456-2467. https://doi.org/10.1056/NEJMoa0805450
|
[48]
|
Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. (2014) Spironolactone for Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine, 370, 1383-1392. https://doi.org/10.1056/NEJMoa1313731
|
[49]
|
McCausland, F.R., Lefkowitz, M.P., Claggett, B., et al. (2020) Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure with Preserved Ejection Fraction. Circulation, 142, 1236-1245. https://doi.org/10.1161/CIRCULATIONAHA.120.047643
|
[50]
|
Martin, N., Manoharan, K., Davies, C., et al. (2021) Beta-Blockers and Inhibitors of the Renin-Angiotensin Aldosterone System for Chronic Heart Failure with Preserved Ejection Fraction. Cochrane Database of Systematic Reviews, 6, CD012721. https://doi.org/10.1002/14651858.CD012721.pub3
|
[51]
|
Riedel, O., Ohlmeier, C., Enders, D., et al. (2018) The Contribution of Comorbidities to Mortality in Hospitalized Patients with Heart Failure. Clinical Research in Cardiology, 107, 487-497. https://doi.org/10.1007/s00392-018-1210-x
|
[52]
|
Tschöpe, C., Birner, C., Böhm, M., et al. (2018) Heart Failure with Preserved Ejection Fraction: Current Management and Future Strategies: Expert Opinion on the Behalf of the Nucleus of the “Heart Failure Working Group” of the German Society of Cardiology (DKG). Clinical Research in Cardiology, 107, 1-19. https://doi.org/10.1007/s00392-017-1170-6
|
[53]
|
Hegde, S.M., Claggett, B., Shah, A.M., et al. (2017) Physical Activity and Prognosis in the TOPCAT Trial (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist). Circulation, 136, 982-992. https://doi.org/10.1161/CIRCULATIONAHA.117.028002
|
[54]
|
O’rourke, M.F., Namasivayam, M. and Adji, A. (2009) Treatment of Hypertension in Patients 80 Years of Age or Older. Minerva Medica, 100, 25-38. https://doi.org/10.1016/S0145-4145(08)79311-0
|
[55]
|
Cikes, M., Claggett, B., Shah, A.M., et al. (2018) Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction: The TOPCAT Trial. JACC: Heart Failure, 6, 689-697. https://doi.org/10.1016/j.jchf.2018.05.005
|
[56]
|
Marrouche, N.F., Brachmann, J., Andresen, D., et al. (2018) Catheter Ablation for Atrial Fibrillation with Heart Failure. The New England Journal of Medicine, 378, 417-427. https://doi.org/10.1056/NEJMoa1707855
|
[57]
|
Ferreira, J.P., Cleland, J.G., Girerd, N., et al. (2023) Spironolactone Effect on Cardiac Structure and Function of Patients with Heart Failure and Preserved Ejection Fraction: A Pooled Analysis of Three Randomized Trials. European Journal of Heart Failure, 25, 108-113. https://doi.org/10.1002/ejhf.2726
|
[58]
|
Yancy, C.W., Jessup, M., Bozkurt, B., et al. (2017) 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136, E137-E161. https://doi.org/10.1161/CIR.0000000000000509
|
[59]
|
Solomon, S.D., Mcmurray, J.J.V., Anand, I.S., et al. (2019) Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. The New England Journal of Medicine, 381, 1609-1620. https://doi.org/10.1056/NEJMoa1908655
|
[60]
|
Anker, S.D., Butler, J., Filippatos, G., et al. (2021) Empagliflozin in Heart Failure with a Preserved Ejection Fraction. The New England Journal of Medicine, 385, 1451-1461. https://doi.org/10.1056/NEJMoa2107038
|
[61]
|
Butt, J.H., Jhund, P.S., Belohlávek, J., et al. (2022) Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial. Circulation, 146, 1210-1224. https://doi.org/10.1161/CIRCULATIONAHA.122.061754
|
[62]
|
Pandey, A.K., Bhatt, D.L., Pandey, A., et al. (2023) Mechanisms of Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure with Preserved Ejection Fraction. European Heart Journal, 44, 3640-3651. https://doi.org/10.1093/eurheartj/ehad389
|
[63]
|
Borlaug, B.A., Reddy, Y.N.V., Braun, A., et al. (2023) Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure with Preserved Ejection Fraction: The CAMEO-DAPA Trial. Circulation, 148, 834-844. https://doi.org/10.1161/CIRCULATIONAHA.123.065134
|
[64]
|
Younes, A.M., Salem, M., Maraey, A., et al. (2022) Safety Outcomes of SGLT2i in the Heart Failure Trials: A Systematic Review and Meta-Analysis. International Journal of Cardiology, 366, 51-56. https://doi.org/10.1016/j.ijcard.2022.06.059
|